Abbott Laboratories Corporation

Gilead Sciences, Inc.

Abbvie Inc.

Other

Devalina Law

Eric Allen Schmitt

Steven L Krill

Kenneth R Phares

James J Fort

Yuerong Hu

Yihong Qiu

Jianguo Ji

Ahmad Y Sheikh

Xiu Chun Wang

Eric J Stoner

William Porter

Alan C Christesen

Agnes E Pal

Daozhong Zou

David B Murphey

William R Porter

A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

Inhibitors of crystallization in a solid dispersion

Solid phases of (&#x2212;)-cis-FTC, which are designated herein as amorphous (&#x2212;)-FTC and Forms II and III (&#x2212;)-cis-FTC) are provided that can be distinguished from Form I (&#x2212;)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (&#xb1;)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B.

Polymorphic and other crystalline forms of cis-FTC

Compounds of formula (II): known as: 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1-H-indole salt with (2R, 3R)-2,3-dihydroxybutanedioic acid (1:1).

Fused bicycloheterocycle substituted quinuclidine derivatives

A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.

Solid dispersion pharamaceutical formulations

Solid phases of (&minus;)-cis-FTC, which are designated herein as amorphous (&minus;)-FTC and Forms II and III (&minus;)-cis-FTC) are provided that can be distinguished from Form I (&minus;)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (&plusmn;)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B.

Polymorphic and other crystalline forms cis-FTC

The present invention is directed to a solid formulation comprising the lipid-regulating agent dispersed in a hydrophilic, amorphous polymer in which said lipid-regulating agent is present as a meta-stable, amorphous phase.

Formulations comprising lipid-regulating agents

Growing community of inventors

Libertyville, IL, United States of America

Devalina Law